Working… Menu

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03294694
Recruitment Status : Active, not recruiting
First Posted : September 27, 2017
Last Update Posted : December 29, 2020
Information provided by (Responsible Party):
Sara Tolaney, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : June 1, 2021
Estimated Study Completion Date : January 1, 2022